作者
Yi Hu, Xin Xu, Yao‐Bin Ouyang, Cong He, Nian‐Shuang Li, Chuan Xie, Chao Peng, Zhen‐Hua Zhu, Yong Xie, Xu Shu, Nong‐Hua Lu, Yin Zhu
发表日期
2022/8
期刊
Helicobacter
卷号
27
期号
4
页码范围
e12896
简介
Background
Vonoprazan‐amoxicillin (VA) dual therapy has been shown to achieve acceptable cure rates for treatment of Helicobacter pylori(H. pylori) in Japan. Its effectiveness in other regions is unknown. We aimed to explore the efficacy of VA dual therapy as first‐line treatment for H. pyloriinfection in China.
Methods
This was a single center, prospective, randomized clinical pilot study conducted in China. Treatment naive H. pyloriinfected patients were randomized to receive either low‐ or high‐dose amoxicillin‐vonoprazan consisting of amoxicillin 1 g either b.i.d. or t.i.d plus VPZ 20 mg b.i.d for 7 or 10 days. 13C‐urea breath tests were used to access the cure rate at least 4 weeks after treatment.
Results
Three hundred and twenty‐three patients were assessed, and 119 subjects were randomized. The eradication rates of b.i.d. amoxicillin for 7 and 10 days, t.i.d. amoxicillin for 7 and 10 days were 66.7 …
引用总数